Dyax Corp. Announces Issuance of Two Key U.S. Patents for DX-2930
September 15 2014 - 7:00AM
Business Wire
Company Expands DX-2930 Intellectual
Property Estate
Dyax Corp. (NASDAQ: DYAX) today announced that the U.S. Patent
and Trademark Office (USPTO) has issued two new patents related to
DX-2930, an investigational fully human monoclonal antibody
inhibitor of active plasma kallikrein. One patent, assigned U.S.
Patent No. 8,816,055, contains claims covering the specific
sequence of DX-2930, and the other, assigned U.S. Patent No.
8,822,653, contains claims covering monoclonal antibodies that bind
to the active form of human plasma kallikrein and do not bind human
pre-kallikrein. Both patents are expected to provide coverage for
DX-2930 until at least 2032.
“These newly issued patents contain broad composition of matter
claims which provide important long-term exclusivity for DX-2930,
especially its binding properties to human plasma kallikrein, which
we believe is a critical target in the treatment for hereditary
angioedema (HAE),” said Gustav Christensen, President and Chief
Executive Officer of Dyax. “Collectively, they further validate
Dyax’s discovery capabilities and confer a unique and robust
intellectual property estate surrounding DX-2930, enhancing its
commercial potential.”
Dyax, a biopharmaceutical company focused on HAE and other
plasma-kallikrein-mediated disorders, is developing DX-2930 as a
subcutaneous injection for prevention of HAE attacks.
About DX-2930
DX-2930 is a novel, fully human monoclonal antibody inhibitor of
active plasma kallikrein (pKal). Uncontrolled pKal activity leads
to excessive generation of bradykinin, a vasodilator thought to be
responsible for the localized swelling, inflammation and pain
characteristically associated with HAE. Dyax is currently
developing DX-2930 as a subcutaneous injection for the prevention
of HAE attacks and expects to report data from a Phase 1b trial
early in 2015.
About HAE
HAE is a rare acute inflammatory condition characterized by
episodes of severe, often painful swelling affecting the
extremities, gastrointestinal tract, genitalia, and larynx. HAE is
caused by low or dysfunctional levels of C1 esterase inhibitor
(C1-INH), a naturally occurring molecule that inhibits plasma
kallikrein, a key mediator of inflammation, and other serine
proteases in the blood. HAE is estimated to affect up to 1 in
50,000 individuals. Learn more at www.HAEHope.com.
About Dyax
Dyax is a fully integrated biopharmaceutical company focused on
the discovery, development and commercialization of novel
biotherapeutics for unmet medical needs. The Company currently
markets KALBITOR® (ecallantide) for the treatment of acute attacks
of HAE in patients 12 years of age and older. Dyax is also
developing DX-2930 for the prophylactic treatment of HAE.
Both KALBITOR and DX-2930 were identified using Dyax's patented
phage display technology. Dyax has broadly licensed this technology
and has a portfolio of product candidates being developed by its
licensees, which it refers to as the Licensing and Funded Research
Portfolio (LFRP). The Company is eligible to receive future
milestones and/or royalties dependent upon the development and
commercialization of these candidates. In April 2014, Dyax’s
licensee Lilly received FDA approval for CYRAMZA™ (ramucirumab) as
a single-agent treatment for patients with advanced gastric cancer
after prior chemotherapy, making this the first approved product
from Dyax’s LFRP.
For additional information about Dyax, please visit www.dyax.com.
For additional information about KALBITOR, including full
prescribing information, please visit www.KALBITOR.com.
Disclaimer
This press release contains forward-looking statements,
including statements regarding the prospects for the clinical
development of DX-2930 and strength of intellectual property and
commercial prospects for DX-2930. Statements that are not
historical facts are based on Dyax’s current expectations, beliefs,
assumptions, estimates, forecasts and projections about the
industry and markets in which Dyax and its licensees compete. The
statements contained in this release are not guarantees of future
performance and involve certain risks, uncertainties and
assumptions, which are difficult to predict. Therefore, actual
outcomes and results may differ materially from what is expressed
in such forward-looking statements because of risks, uncertainties
and assumptions involved in any future projections. There are many
factors that could cause actual results to differ from these
forward-looking statements, including: risks and uncertainties
relating to the clinical development of DX-2930; Dyax's dependence
on the expertise, effort, priorities and contractual obligations of
third parties in the manufacture, quality control, storage and
clinical development of DX-2930; changing requirements and costs
associated with Dyax's planned research and development activities;
competition from new and existing treatments for HAE; the
uncertainty of patent and intellectual property protection; and
other risk factors described or referred to Item 1A, “Risk Factors”
in Dyax’s most recent Annual Report on Form 10-K and other periodic
reports filed with the Securities and Exchange Commission. Dyax
cautions investors not to place undue reliance on the
forward-looking statements contained in this release. These
statements speak only as of the date of this release, and Dyax
undertakes no obligations to update or revise these statements,
except as may be required by law.
Dyax, the Dyax logo and KALBITOR are registered trademarks of
Dyax Corp.
Dyax Corp.Jennifer Robinson, 617-250-5741Director, Investor
Relations and Corporate Communicationsjrobinson@dyax.com
Dyax (NASDAQ:DYAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dyax (NASDAQ:DYAX)
Historical Stock Chart
From Apr 2023 to Apr 2024